Amendment: SEC Form SC 13G/A filed by agilon health inc.

11/6/24 4:47:14 PM ET

Misc Health and Biotechnology Services

Health Care

Get the next $AGL alert in real time by email

SC 13G/A 1 AgilonHealthAGL.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* agilon health, inc. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 00857U107 ----------------------------------------------------- (CUSIP Number) September 30, 2024 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.00857U107 13G Page 2 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 52,197,634 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 55,234,601 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 55,264,825 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 13.4% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.00857U107 13G Page 3 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley Investment Management Inc. I.R.S. # 13-3040307 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 52,122,850 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 55,186,984 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 55,186,984 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 13.4% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: IA, CO -------------------------------------------------------------------------------- CUSIP No.00857U107 13G Page 4 of 8 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: agilon health, inc. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 6210 E HWY 290 SUITE 450 AUSTIN TX 78723 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley (2) Morgan Stanley Investment Management Inc. -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway, New York, NY 10036 (2) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. (2) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 00857U107 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.00857U107 13G Page 5 of 8 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of September 30, 2024.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit 99.2 Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.00857U107 13G Page 6 of 8 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 06, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY Date: November 06, 2024 Signature: /s/ Deidre A. Downes -------------------------------------------------------------------- Name/Title: Deidre A. Downes/Authorized Signatory, Morgan Stanley Investment Management Inc. -------------------------------------------------------------------- Morgan Stanley Investment Management Inc. EXHIBIT NO. EXHIBITS PAGE ----------- ---------- ---- 99.1 Joint Filing Agreement 7 99.2 Item 7 Information 8 * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.00857U107 13G Page 7 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT --------------------------------------------------- November 06, 2024 --------------------------------------------------- MORGAN STANLEY and Morgan Stanley Investment Management Inc. hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley Morgan Stanley Investment Management Inc. BY: /s/ Deidre A. Downes --------------------------------------------------------------------- Deidre A. Downes/Authorized Signatory, Morgan Stanley Investment Management Inc. * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.00857U107 13G Page 8 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.2 ------------------ ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley.

Get the next $AGL alert in real time by email

Recent Analyst Ratings for

$AGL

Date	Price Target	Rating	Analyst
8/20/2025	$1.40	Outperform → Mkt Perform	Bernstein
8/6/2025	$1.00	Buy → Neutral	Citigroup
4/25/2025	$5.00	Neutral → Buy	Citigroup
4/8/2025	$8.50	Mkt Perform → Outperform	Bernstein
1/10/2025	$1.75 → $2.25	Sell → Neutral	Citigroup
1/10/2025		Hold	Needham
12/16/2024		Neutral	Macquarie
12/11/2024	$2.50	Mkt Perform	Bernstein

More analyst ratings

Amendment: SEC Form SC 13G/A filed by agilon health inc.

11/6/24 4:47:14 PM ET

$AGL

Misc Health and Biotechnology Services

Health Care

Get the next $AGL alert in real time by email

Recent Analyst Ratings for

$AGL

Date	Price Target	Rating	Analyst
8/20/2025	$1.40	Outperform → Mkt Perform	Bernstein
8/6/2025	$1.00	Buy → Neutral	Citigroup
4/25/2025	$5.00	Neutral → Buy	Citigroup
4/8/2025	$8.50	Mkt Perform → Outperform	Bernstein
1/10/2025	$1.75 → $2.25	Sell → Neutral	Citigroup
1/10/2025		Hold	Needham
12/16/2024		Neutral	Macquarie
12/11/2024	$2.50	Mkt Perform	Bernstein

More analyst ratings

Amendment: SEC Form SC 13G/A filed by agilon health inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$AGL

Amendment: SEC Form SC 13G/A filed by agilon health inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$AGL

$AGL
Insider Purchases

Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

Chief Markets Officer Shaker Benjamin bought 11,786 shares and covered exercise/tax liability with 4,143 shares, increasing direct ownership by 2% to 457,058 units (SEC Form 4)

$AGL
Press Releases

agilon health Sets Date to Report Third Quarter 2025 Financial Results

agilon health to Participate in the 2025 Jefferies Healthcare Services Conference

agilon health Announces Leadership Transition

$AGL
Analyst Ratings

Agilon Health downgraded by Bernstein with a new price target

Agilon Health downgraded by Citigroup with a new price target

Agilon Health upgraded by Citigroup with a new price target

$AGL
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

SEC Form SCHEDULE 13G filed by agilon health inc.

Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

$AGL
Insider Trading

Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 406 shares, decreasing direct ownership by 0.35% to 114,752 units (SEC Form 4)

Chief Legal Officer Zamore Denise covered exercise/tax liability with 915 shares, decreasing direct ownership by 0.21% to 443,125 units (SEC Form 4)

Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 46,099 shares, decreasing direct ownership by 4% to 1,075,122 units (SEC Form 4)

$AGL
Leadership Updates

agilon health Announces Leadership Transition

agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

agilon health Names Jeff Schwaneke New Chief Financial Officer

$AGL
Financials

agilon health Sets Date to Report Third Quarter 2025 Financial Results

agilon health Sets Date to Report Second Quarter 2025 Financial Results

agilon health Sets Date to Report First Quarter 2025 Financial Results

$AGL
Large Ownership Changes